Inebilizumab有望治疗IgG4-RD

IF 29.4 1区医学 Q1 RHEUMATOLOGY

Nature Reviews Rheumatology Pub Date : 2024-12-11 DOI:10.1038/s41584-024-01206-5

Sarah Onuora

引用次数: 0

摘要

在一项III期试验中，靶向cd19抗体inebilizumab对igg4相关疾病的治疗有效超过52周。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Inebilizumab shows promise for IgG4-RD

In a phase III trial, the CD19-targeting antibody inebilizumab was effective for the treatment of IgG4-related disease over 52 weeks.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Rheumatology 医学-风湿病学

CiteScore

29.90

自引率

0.90%

发文量

137

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Rheumatology is part of the Nature Reviews portfolio of journals. The journal scope covers the entire spectrum of rheumatology research. We ensure that our articles are accessible to the widest possible audience.